937 related articles for article (PubMed ID: 22821401)
1. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
2. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
3. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
4. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
[TBL] [Abstract][Full Text] [Related]
6. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P; Marangoni E; Assayag F; de Cremoux P; Vincent-Salomon A; Guyader Ch; de Plater L; Elbaz C; Karboul N; Fontaine JJ; Chateau-Joubert S; Boudou-Rouquette P; Alran S; Dangles-Marie V; Gentien D; Poupon MF; Decaudin D
Breast Cancer Res Treat; 2012 Jun; 133(2):595-606. PubMed ID: 22002565
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
[TBL] [Abstract][Full Text] [Related]
8. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
Scherer SD; Riggio AI; Haroun F; DeRose YS; Ekiz HA; Fujita M; Toner J; Zhao L; Li Z; Oesterreich S; Samatar AA; Welm AL
Breast Cancer Res; 2021 Oct; 23(1):100. PubMed ID: 34717714
[TBL] [Abstract][Full Text] [Related]
9. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
10. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
12. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
13. New generation breast cancer cell lines developed from patient-derived xenografts.
Finlay-Schultz J; Jacobsen BM; Riley D; Paul KV; Turner S; Ferreira-Gonzalez A; Harrell JC; Kabos P; Sartorius CA
Breast Cancer Res; 2020 Jun; 22(1):68. PubMed ID: 32576280
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.
López-Sánchez LM; Mena R; Guil-Luna S; Mantrana A; Peñarando J; Toledano-Fonseca M; Conde F; De la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Lab Invest; 2021 Mar; 101(3):292-303. PubMed ID: 33262438
[TBL] [Abstract][Full Text] [Related]
15. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
[TBL] [Abstract][Full Text] [Related]
16. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.
Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA
Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413
[TBL] [Abstract][Full Text] [Related]
18. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
19. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor: a never ending story?
Wolff AC; Dowsett M
J Clin Oncol; 2011 Aug; 29(22):2955-8. PubMed ID: 21709205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
